SecBot SecBot
8-K ·Filed Nov 5, 2026

PRTA

PROTHENA CORP PUBLIC LTD CO
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 10h ago SEC0001559053-26-000030
8-K with no item list reported
Actionable Insight • Neutral

Watch for the moponetug Phase 2 data readout in 1H 2027 as the next major binary catalyst. The company's cash runway appears sufficient to fund operations through key milestones without near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

PRTA drug pipeline →

moponetug

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
If Phase 2 data in 1H 2027 is positive, the program would advance to Phase 3 trials, meaning regulatory approval and commercialization are likely several years away (late 2020s at the earliest).
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 2 TargetTau-1 topline readout expected in 1H 2027. Positive data showing both tau biomarker clearance and cognitive benefit could validate the anti-MTBR tau approach and trigger milestone payments from BMS, while negative or mixed results would severely impair Prothena's pipeline value given the recent PRX019 termination. Watch for BMS's Q4 2026 earnings commentary for any trial timing updates.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$7.97
T+0 close · Nov 5, 2026 · via day close
Latest settled
+2.38%
T+5 · $8.16 · next T+20 in 20d
Vs SPY
−0.21%
α at T+5
Latest observation
+1.45%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $7.97entry
  2. T+1 · 8d ago +10.10%α +7.73% · $8.78
  3. T+5 · 4d ago +2.38%α −0.21% · $8.16
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Prothena reported Q3 2026 financial results with a net loss of $16.5M, improved from a $36.5M loss in Q3 2025, driven by lower R&D and G&A expenses. Revenue was minimal at $0.6M for the quarter, while the first nine months included a $50M milestone from Novo. The company has $272.2M in cash, no debt, and maintained 2026 guidance for net cash burn of $18-$23M. Key pipeline catalysts include the moponetug Phase 2 data readout expected in 1H 2027 and Phase 3 trials for prasinezumab and coramitug with primary completions in 2029.

Key Facts

  • Q3 2026 net loss of $16.5M vs $36.5M in Q3 2025
  • Q3 2026 total revenue of $0.6M vs $2.4M in Q3 2025
  • First nine months 2026 total revenue of $52.7M including $50M Novo milestone
  • Cash and restricted cash of $272.2M as of September 30, 2026, no debt
  • Full year 2026 net cash burn guidance maintained at $18-$23M
  • 2,745,380 shares repurchased YTD for $26.6M under $100M buyback program expiring Dec 31, 2026
  • Moponetug Phase 2 data readout expected in 1H 2027
  • Prasinezumab and coramitug Phase 3 trials primary completion expected in 2029

Financial Impact

Net loss improved by $20.0M YoY in Q3; cash position of $272.2M provides runway of approximately 3+ years at current burn rate

net lossrevenuecash positionoperating expenses

Risk Factors

  • All three partnered programs (prasinezumab, coramitug, moponetug) are in early-to-mid stage trials with no approved products
  • Phase 3 data for lead programs not expected until 2029, creating a long wait for potential commercialization
  • Revenue is entirely dependent on partner milestones and collaboration payments, with no product sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001559053-26-000030
Document: prta-20261105.htm0001559053-26-000030
Document: 0001559053-26-000030-index-headers.html0001559053-26-000030
Document: 0001559053-26-000030-index.html0001559053-26-000030
Document: 0001559053-26-000030.txt0001559053-26-000030

Track record

20 reports on PRTA

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+1. Best: +14.11% at T+60 after the Jun 12, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago 3 Neutral 1/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
  3. Nov 10, 20266d ago Insider Buy Bullish 5/10 Entry $8.56 to $8.73 Now $7.97 −6.89% ▲ +1.99% +0.67% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $7.97 to $8.78 Now $7.97 −0.00% ▲ +10.10% +7.73% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $8.47 to $8.29 Now $7.97 +5.90% ▲ +2.13% +1.65% vs SPY
  6. Oct 26, 202621d ago Insider Buy Bullish 5/10 Entry $8.81 to $9.10 Now $7.97 −9.53% ▲ +3.29% +2.95% vs SPY
  7. Oct 15, 20264w ago Insider Buy Bullish 5/10 Entry $8.35 to $8.48 Now $7.97 −4.55% ▲ +1.56% +1.13% vs SPY
  8. Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $8.54 to $8.36 Now $7.97 −6.67% ▼ −2.11% −2.85% vs SPY
  9. Sep 29, 20266w ago Insider Buy Bullish 5/10 Entry $8.38 to $8.54 Now $7.97 −4.89% ▲ +1.91% +1.73% vs SPY
  10. Sep 21, 20268w ago Insider Buy Bullish 6/10 Entry $8.99 to $8.68 Now $7.97 −11.35% ▼ −3.45% −2.73% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026